Acute on Chronic Theophylline Toxicity in an Elderly Patient

Alexander Kong, Somshukla Ghosh, Chelsea Guan, Brittany L. Fries, Floyd W. Burke

Abstract

Theophylline toxicity has become rare in the 21st century, as the drug has fallen out of favor due to serious life-threatening adverse events, narrow therapeutic window and readily available therapeutic alternatives. The wide array of clinical symptoms related to theophylline toxicity makes this diagnosis challenging for the treating physician. We report a case of an elderly gentleman who presented with respiratory failure and seizures due to severe theophylline toxicity.

Introduction

Theophylline is a methylxanthine used for the treatment of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and apnea of prematurity, due to its pharmacological action in smooth muscle relaxation, anti-inflammatory properties and powerful stimulation of the central nervous system (CNS) respiratory center [1]. The narrow therapeutic range (serum concentration 10 to 20 mcg/mL for adults) and the concomitant use of certain medications that impair theophylline clearance make individualized dosing critical and underscore the need for frequent serum theophylline concentration monitoring [2-4]. Life-threatening toxicity is associated with serum concentrations of 80 to 100 mcg/mL in acute overdoses and 40 to 60 mcg/mL in chronic overdoses [5]. Additionally, acute-on-chronic toxicity can occur with acute overdoses in adults already being treated with therapeutic theophylline [6]. Life-threatening theophylline toxicity remains a concern throughout treatment duration, especially in the elderly due to potential alterations in theophylline pharmacokinetics, increase in interacting medications and/or improper adherence resulting in overdosing [4,6,7].

Theophylline toxicity can present with a wide array of clinical manifestations, ranging from mild gastrointestinal complaints to potentially lethal cardiac arrhythmias and seizures. Its non-specific symptom presentations combined with the decreased use of theophylline in the 21st century make it a diagnostic challenge, requiring a high level of suspicion [8]. This is true even though the pharmacokinetics, clinical syndrome and risk factors for developing theophylline toxicity are well documented in the literature.

We present a case of an elderly patient, treated chronically with theophylline for severe asthma-COPD overlap, who developed severe theophylline toxicity in the setting of an acute exacerbation. The aim of this report is to provide a current, problem-based example of the typical clinical picture of theophylline toxicity in order to increase physician awareness of this infrequent entity, reinforce the importance of patient education and routine drug level monitoring in long-term therapy and in acute exacerbations.

Case Presentation

An 83-year-old male with a past medical history of coronary artery disease, hypertension, severe persistent asthma, COPD GOLD stage 2D, gastroesophageal reflux disease and hypothyroidism presented to the emergency department due to an episode of witnessed generalized tonic-clonic seizure that was preceded by a one-day history of non-bloody, non-bilious vomiting and throat tightness. On presentation, the patient was agitated, oriented to only himself and showed significantly increased work of breathing with the use of accessory muscles. Vital signs showed a temperature of 97.4 °F, blood pressure of 134/81 mmHg, heart rate of 146 beats per minute and respiratory rate of 26 breaths per minute. Mucous membranes were dry, and he had decreased skin turgor. The respiratory exam showed good chest excursions, poor air entry at the bases of 146 beats per minute and respiratory rate of 26 breaths per minute. The cardiovascular exam was unremarkable other than sinus tachycardia. Neurologically, the patient was alert, awake, oriented with normal speech and mentation, moving all extremities with preserved motor strength. Electrocardiogram (Figure 1) and telemetry showed wide-QRS-complex tachycardia that was unresponsive to intravenous adenosine. A basic metabolic panel (Table 1) showed combined metabolic and respiratory acidosis, hypokalemia with a potassium level of 2.2 mEq/L, acute kidney injury with a creatinine of 1.4 mg/dL (baseline 0.8 mg/dL) and thyroid-stimulating hormone level of 0.829 mIU/L.

How to cite this article
Kong A, Ghosh S, Guan C, et al. (February 22, 2021) Acute on Chronic Theophylline Toxicity in an Elderly Patient. Cureus 13(2): e13484. DOI 10.7759/cureus.13484
The patient was admitted to the intensive care unit for monitoring. On serial examination, the patient developed seizure activity, becoming non-responsive, unable to protect his airway and required emergent rapid-sequence intubation and mechanical ventilation.

The patient’s medication reconciliation (see Appendix, Table 2) included extended-release theophylline 300 mg capsules once daily, which he had been taking as usual (last administration day of presentation). There were no new medication changes with the exception of a recent course of sulfamethoxazole/trimethoprim tablets for a urinary tract infection. On laboratory testing, theophylline level was supratherapeutic at 80.7 mcg/mL (therapeutic range 10-20 mcg/mL). The patient was treated for theophylline toxicity with hemodialysis without ultrafiltration, for a total of seven hours. Serum theophylline level gradually lowered to therapeutic levels, with the resolution of electrolyte abnormalities, metabolic acidosis and cardiac arrhythmias. The patient did not have any further episodes of seizures. Mental status progressively improved and he was able to be extubated on hospital day 4. A severe adverse reaction to theophylline was documented in the patient’s electronic medical record and theophylline was permanently discontinued.

**Discussion**

Given high mortality risk if cardiac arrhythmias or seizures are present, suspicion for theophylline toxicity at
entry into the Emergency Department, and prompt initiation of emergency management is paramount for favorable outcomes, particularly in the elderly [4,6]. Physicians must have a high index of suspicion and medication reconciliation is of utmost importance [9]. In our patient, sub-optimal communication with the patient’s spouse and spouse misunderstanding of medication therapy delayed historical evidence of theophylline use.

Our patient presented with a constellation of gastrointestinal, cardiovascular, central nervous systems and metabolic derangements consistent with hyperadrenergic stimulation [10]. Toxic theophylline levels cause phosphodiesterase inhibition and consequently increase systemic levels of cyclic adenosine monophosphate, which augments beta-adrenergic effects. Its combined effect as an adenosine antagonist promotes smooth muscle relaxation, myocardial stimulation, increased chronotropism and inotropism, CNS excitation, increased muscle oxygen consumption and increased basal metabolic rate eventually leading to metabolic acidosis [5].

The management of this patient was initially symptom-based. Cardiac monitoring showed wide QRS complex tachycardia that was not responsive to intravenous adenosine, however at that time theophylline toxicity was not suspected. Adenosine has been recommended as first-line therapy by some experts to reverse theophylline–induced supraventricular tachycardia (SVT). However, given theophylline acts as an adenosine antagonist, failure to convert a methylxanthine-induced SVT with adenosine is common [5]. In addition, adenosine should be used with extreme caution in patients with asthma or COPD, given it poses a paradoxical risk for bronchoconstriction. Even though SVT and other atrial tachycardias are the most common arrythmias induced by theophylline, the patient’s severe electrolyte disturbances could have also caused ventricular tachycardia [6]. The electrolyte disturbances were likely secondary to both surreptitious vomiting and theophylline toxicity.

Our patient’s respiratory depression could have been due to transient seizures or directly related to theophylline toxicity. Severe theophylline toxicity can cause hyperventilation, respiratory alkalosis, respiratory failure, respiratory arrest and acute respiratory distress syndrome [5]. Nonetheless, severe transient respiratory changes with hypercapnia and hypoxemia can also be present during seizure episodes [11]. In our case, our patient presented with tachypnea, likely related to direct ventilatory overstimulation by theophylline, and later seizure-induced respiratory depression leading to acute hypercapnic respiratory failure.

There are no antidotes to reverse the toxic effects of theophylline; therefore, therapy is focused on enhancing its elimination. In acute overdose, gastric decontamination with multi-dose activated charcoal (MDAC) is initially recommended if the patient is able to protect the airway, although it is often limited by intractable vomiting or ineffectiveness at reducing theophylline concentrations [12]. Extracorporeal treatment (ECTR) is more effective at removing theophylline than MDAC and hemodialysis is preferred over hemoperfusion [5,12,15]. ECTR is indicated at theophylline concentrations over 100 mcg/mL in acute exposure and suggested for theophylline concentration over 60 mcg/mL in chronic exposure. A lower threshold (over 50 mcg/mL) has been suggested if the patient is less than six months or more than 60 years old. ECTR is also indicated based on symptoms such as life-threatening dysrhythmias, seizures, mental status changes or hypotension [12]. Some recommendations are based on contraindications to administer MDAC, serious comorbidities or coexisting conditions such as COPD, end-stage renal disease and liver failure [12]. Our patient fulfilled multiple criteria for ECTR due to altered mental status, seizure activity, electrolyte abnormalities, wide-complex tachycardia, theophylline concentration of 80.7 mcg/mL, elderly age, numerous comorbidities and suspected acute-on-chronic toxicity. The patient underwent hemodialysis without ultrafiltration for seven hours during which he rapidly reverted to sinus rhythm, his serum electrolytes were corrected, and his seizures resolved.

This patient’s supratherapeutic theophylline level was attributed to self-administered inadvertent overuse of his chronic therapy triggered by an acute exacerbation of his asthma-COPD overlap. Hyperthyroidism may increase metabolism of theophylline and likewise, metabolism may be reduced with hypothyroidism. Thyroid replacement may affect theophylline clearance in patients that are not stabilized (i.e. euthyroid); however, our patient’s most recent TSH was 0.829 mIU/L and, therefore, this was not suspected to have been a major contributing factor. Ipriflavone, a component of his antioxidant blend, has been associated with increased theophylline levels in two cases, thought to be due to a decrease in CYP 1A2 metabolism. Similarly, the black pepper component of turmeric compounds may be associated with increased absorption and reduced elimination of theophylline; however, these mechanisms are theoretical and poorly documented [14]. Recent sulfamethoxazole/trimethoprim and concurrent non-steroidal anti-inflammatory agents may have contributed to acute kidney injury, which may have resulted in reduced theophylline clearance. Since theophylline undergoes extensive hepatic metabolism, mediated by cytochrome P450 enzymes (CYPs), it can be enhanced by CYP inducers, such as phenytoin or phenobarbital, or reduced by CYP inhibitors, such as cinetidine and macrolides [15]. These CYPs have also been suggested to become inhibited in the setting of upper respiratory disease with associated fever [16]. The American Geriatric Society Beers Criteria warns that the concurrent use of cinetidine or ciprofloxacin with theophylline increases the risk of theophylline toxicity [17]. Over-the-counter (OTC) vitamin and herbal supplement use could have potentially interfered with theophylline metabolism. It is important to note that interactions between dietary supplements and prescription drugs are usually unknown as most of these supplements are
not regulated by the US Food and Drug Administration [18]. Healthcare providers should remain vigilant and educate patients on the potential risks of OTC pharmaceuticals or "nutraceuticals", especially when taking drugs with a narrow therapeutic index.

In our case, patient education on theophylline use and increased awareness of chronic theophylline toxicity may have helped prevent unintentional toxicity. Drug level monitoring is strongly advised at initiation, dosing changes, routinely (at least yearly) and when other medications are added, changed or discontinued, or there is a new illness that may alter theophylline clearance [2]. Our patient did not have theophylline serum monitoring in over three years despite continued refills and close follow up. In general, we recommend that prescription for this medication should always be individualized and reconsidered, given the high risk for life-threatening adverse effects and multiple, safer therapeutic alternatives for bronchodilation in the market.

**Conclusions**

Theophylline toxicity is a life-threatening, challenging diagnosis due to its wide array of multi-organ non-specific clinical symptoms. Changes in mental status and lack of family availability may further hinder the diagnosis if an updated medication list is unavailable. A high index of suspicion is necessary for the prompt implementation of emergent procedures to reduce morbidity and mortality. Due to its narrow therapeutic index, prescribing theophylline should be strongly reconsidered, and if prescribed, the risk and benefits should be thoroughly discussed with the patient.

**Appendices**
Medications and supplements retrieved from the patient’s home.

| Description                                                                 | Dosage                        | Route          |
|----------------------------------------------------------------------------|-------------------------------|----------------|
| 1 empty bottle Rx sulfamethoxazole 830 mg trimethoprim 160 mg 1 tab PO QD |                               |                |
| 1 unlabeled bottle Rx with unidentified pills                            |                               |                |
| Amlodipine besylate 10 mg 1 tab PO QD                                    |                               |                |
| Aspirin 81 mg 1 tab PO QD                                                |                               |                |
| Blue Green Algae (KFA) Aphanizomenon flos-aquae Powder 1 cap PO QD        |                               |                |
| Cow colostrum/chicken egg yolk/don/horse/shiitake/myrica/kelp blend 1 cap PO QD |                               |                |
| Docusate sodium 100 mg 1 cap PO BID                                      |                               |                |
| Ferrum glycine 224 mg 1 tab PO TID                                       |                               |                |
| Hydroxyzine HCl 10 mg 2 tab PO QHS                                       |                               |                |
| Melatonin 10 mg 1 tab PO QHS                                              |                               |                |
| Melatonin/fruit/algae/chicken egg yolk/don/horse/shiitake/myrica/kelp blend 1 tab PO QHS |                               |                |
| Methocarbamol 500 mg 1 tab PO QID                                        |                               |                |
| Mometasone furoate inhalation powder 130 mcg 2 puffs INH BID             |                               |                |
| Multivitamin/coenzymeQ10/Olive fatty acid/fish oil/antioxidant blend 1 cap PO QD |                               |                |
| Naproxen 500 mg 1 tab PO BID                                              |                               |                |
| Omeprozole 20 mg 2 cap PO BID                                             |                               |                |
| Oxymetazoline HCl 0.05% nasal spray 1 application in each nostril PRN BID |                               |                |
| Potassium chloride 20 Meq SA 1 tab PO QD                                 |                               |                |
| Steroidsolone 80 mg 1 tab PO TID                                         |                               |                |
| Sucralfate 1 g cap PO QD                                                  |                               |                |
| Theophylline 300 mg SA 1 cap PO QD                                       |                               |                |
| Turmeric powder 500 mg 1 cap PO QD                                       |                               |                |

**TABLE 2:** Medications and supplements retrieved from the patient’s home.

PO: orally, INH: oral inhalation, QD: daily, BID: twice daily, TID: three times daily, QID: four times daily, QHS: at bedtime, PRN: as needed, tab: tablet, cap: capsule, SA: sustained action.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. HCA Healthcare issued approval 2020-801. Based on the information provided and attested as true, the research plan described does not require IRB oversight. This is because you are either a) not engaging in research with human subjects as defined by federal regulations; b) engaging in research with human subjects deemed excluded from IRB oversight per 45CFR46.102(l) or c) engaging in research with sufficient human subject protections in the design to meet one or more IRB exemption criteria set forth in 45CFR46.104.  **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Barnes PJ: Theophylline. Pharmaceuticals (Basel). 2010, 3:725-747. 10.3390/ph3030725
2. Theophylline. (2020). Accessed: December 20, 2020: https://www.ncbi.nlm.nih.gov/books/NBK519024/
3. Perry H: Theophylline poisoning. UpToDate. 2020, 1:20.
4. Sessler CN: Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med. 1990, 88:567-576. 10.1016/0002-9343(90)90519-J
5. Hoffman RJ: Goldfrank’s Toxicologic Emergencies, 11th edition. McGraw-Hill Education, New York; 2019.
6. Shannon M: Predictors of major toxicity after theophylline overdose. Ann Intern Med. 1993, 119:1161-1167. 10.7326/0003-4819-119-12-199312150-00002
7. Shannon M: Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med. 1999, 159:989-994. 10.1001/archinte.159.9.989
8. Gummin DD, Mowry JB, Spyker DA, et al.: 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th annual report. Clin Toxicol (Phila). 2019, 57:120-1415. 10.1080/15563650.2019.1677022
9. Hopkins ME, MacKenzie-Ross RV: Case report: the risks associated with chronic theophylline therapy and measures designed to improve monitoring and management. BMC Pharmacol Toxicol. 2016, 17:13. 10.1186/s40360-016-0050-4
10. Hall KW, Dobson KE, Dalton IG, et al.: Metabolic abnormalities associated with intentional theophylline overdose. Ann Intern Med. 1984, 101:457-462. 10.7326/0003-4819-101-4-457
11. Soyal M, Bateman LM, Albertson TE, et al.: Respiratory changes with seizures in localization-related epilepsy: analysis of periictal hypercapnia and airflow patterns. Epilepsia. 2010, 51:1359-1364. 10.1111/j.1528-1167.2009.02518.x
12. Ghannoun M, Wiegand TJ, Liu KD, et al.: Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol. 2015, 53:215-229. 10.3109/15563650.2015.1014907
13. Stegeman CA, Jordans IG: Theophylline intoxication, clinical features, treatment and outcome: a case report and a review of the literature. Ned T. Med. 1991, 39:115-125. 000
14. Yacobucci KL: Natural Medicines. Therapeutic Research Center, Somerville, MA; 2020.
15. Gaudreault P, Guay J: Theophylline poisoning. Pharmaceutical considerations and clinical management. Med Toxicol. 1986, 1:169-191. 10.1007/BF03259856
16. Chang KC, Bell TD, Lauer BA, Chai H: Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978, 1:1132-1135. 10.1016/s0140-6736(78)90365-7
17. Fick DM, Semsis TP, Steinman M, et al.: American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019, 67:674-694. 10.1111/jgs.15767
18. The Lancet: Dietary supplement regulation: FDA’s bitter pill. Lancet. 2019, 395:718. 10.1016/S0140-6736(19)30406-4